PT - JOURNAL ARTICLE AU - Atienza-Diez, Iker AU - Seoane, Luís F TI - Long- and short-term effects of cross-immunity in epidemic dynamics AID - 10.1101/2022.04.04.22273361 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.04.22273361 4099 - http://medrxiv.org/content/early/2022/04/05/2022.04.04.22273361.short 4100 - http://medrxiv.org/content/early/2022/04/05/2022.04.04.22273361.full AB - The vertebrate immune system is capable of strong, focused adaptive responses that depend on T-cell specificity in recognizing antigenic sequences of a pathogen. Recognition tolerance and antigenic convergence cause cross-immune reactions that extend prompt, specific responses to rather similar pathogens. This suggests that reaching herd-immunity might be facilitated during successive epidemic outbreaks (e.g., SARS-CoV-2 waves with different variants). Qualitative studies play down this possibility because cross-immune protection is seldom sterilizing. We use minimal quantitative models to study how cross-immunity affects epidemic dynamics over short and long timescales. In the short scale, we investigate models of sterilizing and attenuating immunity, finding equivalences between both mechanisms—thus suggesting a key role of attenuating protection in achieving herd immunity. Our models render maps in epidemic-parameter space that discern threatening variants depending on acquired cross-immunity levels. We illustrate this application with SARS-CoV-2 data, including protection due to vaccination rates across countries. In the long-time scale, we model sterilizing cross-immunity between rolling pathogens to characterize statistical properties of successful strains. We find that sustained cross-immune protection alters the regions of epidemic-parameter space where large outbreaks happen. Our results suggest an optimistic revision concerning prospects for herd protection based on cross-immunity, including for the SARS-CoV-2 pandemics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementBoth IA-D and LFS were supported by grant PID2020-113284GB-C21, funded by MCIN/AEI/10.13039/501100011033. LFS has received funding from the Spanish National Research Council (CSIC) and the Spanish Department for Science and Innovation (MICINN) through a Juan de la Cierva Fellowship (IJC2018-036694-I), and from the Spanish "Instituto de Salud Carlos III and the Ministerio de Ciencia e Innovacion" through the research grant COV20/00617 entitled PREDICO. The Spanish MICINN has also funded the "Severo Ochoa" Centers of Excellence distinction for the CNB, where this research was carried out (grant SEV 2017-0712), and the special grant PIE 2020-20E079 (awarded to the CNB) entitled "Development of protection strategies against SARS-CoV-2".Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data is contained or can be reproduced from the equations in the manuscript.